IA
PRLD icon

IndexIQ Advisors’s Prelude Therapeutics PRLD Stock Holding History

IndexIQ Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$392K Buy
+56,750
New +$519K 0.01% 814

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

IndexIQ Advisors's PRLD Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Prelude Therapeutics (PRLD) in Q1 2022: 56,750 shares worth $392K. The stake represents 0.01% of the portfolio and ranks #814 among its holdings.

68 funds tracked by Wall St. Rank hold PRLD as of Q1 2022.

  • IndexIQ Advisors held 56,750 shares of Prelude Therapeutics worth $392K as of Q1 2022.
  • Prelude Therapeutics was a new IndexIQ Advisors position in Q1 2022.
  • Prelude Therapeutics made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #814 holding.
  • 68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.